Fernando Scudiero
Overview
Explore the profile of Fernando Scudiero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
489
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Di Vece D, Bellino M, Silverio A, Migliarino S, Bossone E, Scudiero F, et al.
JACC Cardiovasc Imaging
. 2024 Sep;
18(1):119-121.
PMID: 39230534
No abstract available.
2.
Piedimonte G, Cerrato E, Rolfo C, Nunez Gil I, Azzalini L, Mangione R, et al.
Cardiovasc Revasc Med
. 2024 Aug;
PMID: 39181812
Background: The optimal strategy during percutaneous coronary intervention (PCI) of aneurysmatic right coronary artery (ARCA) remains uncertain and has never been tested in the acute setting. Objectives: To compare the...
3.
Silverio A, Bellino M, Scudiero F, Attisano T, Baldi C, Catalano A, et al.
J Thromb Thrombolysis
. 2024 Apr;
57(5):757-766.
PMID: 38615155
The use of intravenous antiplatelet therapy during primary percutaneous coronary intervention (PPCI) is not fully standardized. The aim is to evaluate the effectiveness and safety of periprocedural intravenous administration of...
4.
Silverio A, Bossone E, Parodi G, Scudiero F, Di Maio M, Vriz O, et al.
Eur J Prev Cardiol
. 2023 Jul;
30(18):1998-2005.
PMID: 37463434
Aims: The aim of this study was to investigate the long-term outcome of takotsubo syndrome (TTS) patients with and without hypertension (HT) and to evaluate the effectiveness of treatment with...
5.
Canonico M, Sanna G, Siciliano R, Scudiero F, Esposito G, Parodi G
Front Pharmacol
. 2022 Aug;
13:916361.
PMID: 36016569
Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease affecting over 71 million people worldwide. An increased incidence of atherothrombotic events [e.g. coronary artery disease...
6.
Scudiero F, Muraca I, Migliorini A, Marcucci R, Pennesi M, Mazzolai L, et al.
J Interv Cardiol
. 2022 May;
2022:6496777.
PMID: 35494423
Background: This study is aimed at comparing the clinical outcomes of unprotected left main coronary artery disease (ULMCAD) treatment with contemporary percutaneous coronary intervention (PCI) or coronary artery bypass grafting...
7.
Silverio A, Parodi G, Scudiero F, Bossone E, Di Maio M, Vriz O, et al.
Heart
. 2022 Apr;
108(17):1369-1376.
PMID: 35361673
Objective: The advantage of beta-blockers has been postulated in patients with Takotsubo syndrome (TTS) given the pathophysiological role of catecholamines. We hypothesised that beta-blocker treatment after discharge may improve the...
8.
Russo V, Silverio A, Scudiero F, DAndrea A, Attena E, Di Palma G, et al.
Medicina (Kaunas)
. 2022 Mar;
58(3).
PMID: 35334575
Background and objectives: Pre-existing atrial fibrillation (AF) is a frequent comorbidity in hospitalized patients with COVID-19; however, little is still known about its prognostic role in infected patients. The aim...
9.
Scudiero F, Silverio A, Muraca I, Russo V, Di Maio M, Silvestro A, et al.
J Pers Med
. 2022 Feb;
12(2).
PMID: 35207651
The characteristics and clinical course of hospitalized patients with coronavirus disease 2019 (COVID-19) have been widely described, while long-term data are still poor. The aim of this study was to...
10.
Scudiero F, Canonico M, Sanna G, Dossi F, Silverio A, Galasso G, et al.
Cardiovasc Drugs Ther
. 2022 Feb;
37(4):695-703.
PMID: 35175499
Purpose: This study aims to assess the association between body mass index (BMI) and platelet reactivity in STEMI patients treated with oral 3 generation P2Y inhibitors. Methods: Overall, 429 STEMI...